Bristol-Myers Squibb Company (BMY) Shares Bought by Winslow Evans & Crocker Inc.
Winslow Evans & Crocker Inc. grew its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 28.1% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,304 shares of the biopharmaceutical company’s stock after buying an additional 5,324 shares during the quarter. Winslow Evans & Crocker Inc.’s holdings in Bristol-Myers Squibb were worth $1,351,000 at the end of the most recent reporting period.
Several other institutional investors also recently added to or reduced their stakes in the company. State Street Corp boosted its holdings in shares of Bristol-Myers Squibb by 1.8% in the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock valued at $3,746,446,000 after buying an additional 1,223,457 shares during the period. Jennison Associates LLC boosted its holdings in shares of Bristol-Myers Squibb by 0.8% in the first quarter. Jennison Associates LLC now owns 21,927,898 shares of the biopharmaceutical company’s stock valued at $1,192,439,000 after buying an additional 178,436 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of Bristol-Myers Squibb by 18.7% in the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock valued at $845,504,000 after buying an additional 2,451,390 shares during the period. Legal & General Group Plc boosted its holdings in shares of Bristol-Myers Squibb by 4.3% in the first quarter. Legal & General Group Plc now owns 8,213,428 shares of the biopharmaceutical company’s stock valued at $446,664,000 after buying an additional 335,795 shares during the period. Finally, Swiss National Bank boosted its holdings in shares of Bristol-Myers Squibb by 27.2% in the first quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock valued at $322,020,000 after buying an additional 1,267,900 shares during the period. Institutional investors own 68.88% of the company’s stock.
Shares of Bristol-Myers Squibb Company (BMY) traded down 0.47% during mid-day trading on Thursday, reaching $64.05. 2,187,136 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $61.15 and its 200 day moving average price is $56.54. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $64.79. The company has a market cap of $105.04 billion, a PE ratio of 23.39 and a beta of 1.19. Bristol-Myers Squibb also was the recipient of unusually large options trading activity on Wednesday. Traders purchased 37,577 call options on the company. This is an increase of 274% compared to the average volume of 10,041 call options.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.01. The firm had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.69 EPS. On average, equities research analysts predict that Bristol-Myers Squibb Company will post $2.98 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 2.41%. The ex-dividend date is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is 56.73%.
In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Theodore R. Samuels II acquired 6,000 shares of the business’s stock in a transaction on Wednesday, August 2nd. The shares were purchased at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the acquisition, the director now directly owns 18,000 shares in the company, valued at $1,006,920. The disclosure for this purchase can be found here. 0.23% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: This news story was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/bristol-myers-squibb-company-bmy-shares-bought-by-winslow-evans-crocker-inc/1610906.html.
BMY has been the subject of several research analyst reports. Hilliard Lyons cut shares of Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price target for the company. in a report on Tuesday, September 12th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $65.00 price target (up previously from $62.00) on shares of Bristol-Myers Squibb in a report on Thursday, September 7th. Jefferies Group LLC upped their price target on shares of Bristol-Myers Squibb from $66.00 to $72.00 and gave the company a “buy” rating in a report on Monday, September 11th. Piper Jaffray Companies set a $60.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Thursday, July 27th. Finally, BMO Capital Markets reiterated a “sell” rating and issued a $49.00 price target on shares of Bristol-Myers Squibb in a report on Monday, September 4th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and nine have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $61.84.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.